GlassScriptPhysician profile
William P Baugh
NPI 1891725602
$4,434.34
in general payments reported to CMS, 2019-2025
30 companies · $586 in 2025
The $586 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $347 · 2021: $673 · 2022: $768 · 2023: $858 · 2024: $634 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,999 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.14 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,237.39 | 2019-2025 | Dupixent |
| Abbvie INC. | $641.94 | 2019-2025 | Skyrizi |
| Genzyme Corporation | $529.41 | 2019-2025 | |
| Merz North America, INC. | $235.59 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $235.48 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $229.90 | 2021-2025 | |
| Janssen Biotech, INC. | $211.47 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Biofrontera INC. | $139.77 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Lilly USA, LLC | $111.91 | 2020-2021 | |
| Stemline Therapeutics INC. | $104.07 | 2021 | |
| Sanofi-Aventis U.S. LLC | $93.50 | 2021-2024 | |
| Pfizer INC. | $91.69 | 2020-2023 | |
| Leo Pharma INC. | $73.95 | 2019-2022 | |
| Galderma Laboratories, L.P. | $67.22 | 2019-2020 | |
| Allergan, INC. | $53.94 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $41.51 | 2019-2023 | Klisyri |
| Arcutis Biotherapeutics, INC. | $36.97 | 2023 | |
| Organon LLC | $32.46 | 2025 | Vtama |
| Mission Pharmacal Company | $32.30 | 2019 | |
| Ucb, INC. | $32.28 | 2019-2021 | |
| Organogenesis INC. | $29.73 | 2024 | Cygnus Dual |
| Mayne Pharma Commercial LLC | $27.35 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $26.32 | 2023 | Sotyktu |
| Incyte Corporation | $24.54 | 2023 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.42 | 2019 | |
| Sebela Pharmaceuticals INC. | $17.38 | 2020 | |
| Prugen, INC. Pharmaceuticals | $16.61 | 2019 | |
| Epi Health, LLC | $15.25 | 2019 | |
| Tactile Systems Technology INC | $15.05 | 2020 | |
| Medimetriks Pharmaceuticals, INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Baugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.